MA56196A - Pyrazolo-pyridine amides substitués et leur utilisation en tant que modulateurs du récepteur glun2b - Google Patents
Pyrazolo-pyridine amides substitués et leur utilisation en tant que modulateurs du récepteur glun2bInfo
- Publication number
- MA56196A MA56196A MA056196A MA56196A MA56196A MA 56196 A MA56196 A MA 56196A MA 056196 A MA056196 A MA 056196A MA 56196 A MA56196 A MA 56196A MA 56196 A MA56196 A MA 56196A
- Authority
- MA
- Morocco
- Prior art keywords
- pyrazolo
- receptor modulators
- substituted amides
- pyridine substituted
- glun2b receptor
- Prior art date
Links
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical group C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 title 1
- 108010054200 NR2B NMDA receptor Proteins 0.000 title 1
- 150000001408 amides Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861656P | 2019-06-14 | 2019-06-14 | |
| PK35020 | 2020-06-03 | ||
| ARP200101623A AR119125A1 (es) | 2019-06-14 | 2020-06-09 | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56196A true MA56196A (fr) | 2022-04-20 |
Family
ID=73781829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056196A MA56196A (fr) | 2019-06-14 | 2020-06-12 | Pyrazolo-pyridine amides substitués et leur utilisation en tant que modulateurs du récepteur glun2b |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11618750B2 (fr) |
| EP (1) | EP3983075A1 (fr) |
| KR (1) | KR20220024511A (fr) |
| CN (1) | CN113993868A (fr) |
| AU (1) | AU2020290016A1 (fr) |
| BR (1) | BR112021024856A2 (fr) |
| CA (1) | CA3142996A1 (fr) |
| CL (1) | CL2021003277A1 (fr) |
| CO (1) | CO2021016003A2 (fr) |
| CR (1) | CR20210580A (fr) |
| DO (1) | DOP2021000251A (fr) |
| EC (1) | ECSP21090478A (fr) |
| IL (1) | IL288859A (fr) |
| JO (1) | JOP20210328A1 (fr) |
| MA (1) | MA56196A (fr) |
| MX (1) | MX2021015506A (fr) |
| PE (1) | PE20220386A1 (fr) |
| SG (1) | SG11202112407PA (fr) |
| TW (1) | TW202112774A (fr) |
| WO (1) | WO2020249792A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
| CR20210580A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b |
| BR112021025136A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Pirazolo[4,3-b]piridinas substituídas e seu uso como moduladoras do receptor de glun2b |
| JP7667097B2 (ja) | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ.ベー. | 置換ピラゾロ-ピリジンアミド及びglun2b受容体調節因子としてのその使用 |
| US11459336B2 (en) | 2019-06-14 | 2022-10-04 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as GluN2B receptor modulators |
| WO2020249802A1 (fr) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Pyrazolo-pyrazines substituées et leur utilisation en tant que modulateurs du récepteur de glun2b |
| MX2021015508A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Carbamatos de piridina y su uso como moduladores del receptor glun2b. |
| WO2020249785A1 (fr) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Pyrazolo-pyridines hétéroaromatiques substituées et leur utilisation en tant que modulateurs du récepteur glun2b |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9407447D0 (en) | 1994-04-14 | 1994-06-08 | Glaxo Group Ltd | Chemical compounds |
| DE69730980T2 (de) | 1996-07-31 | 2006-02-23 | Nikken Chemicals Co., Ltd. | 6-phenyltetrahydro-1,3-oxazin-2-on derivate und medizinische zusammensetzungen, die sie enthalten |
| WO2002000629A1 (fr) | 2000-06-26 | 2002-01-03 | Merck & Co., Inc. | Antagonistes des recepteurs nmda nr2b de l'iminopyrimidine |
| US6610723B2 (en) | 2001-01-29 | 2003-08-26 | Hoffmann-La Roche Inc. | Imidazole derivatives |
| AU2003214412A1 (en) | 2002-03-28 | 2003-10-13 | Eisai R & D Management Co., Ltd. | 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders |
| US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| TW200406385A (en) | 2002-05-31 | 2004-05-01 | Eisai Co Ltd | Pyrazole compound and pharmaceutical composition containing the same |
| EA200601266A1 (ru) | 2004-02-18 | 2007-02-27 | Астразенека Аб | Соединения триазола и их применение в качестве антагонистов метаботропного рецептора глутамата |
| CA2581454A1 (fr) | 2004-09-23 | 2006-03-30 | Reddy Us Therapeutics, Inc. | Nouveaux composes de pyrimidine, leur procede de preparation, et compositions les contenant |
| WO2007115231A2 (fr) | 2006-03-30 | 2007-10-11 | Chemocentryx, Inc. | Modulateurs de cxcr4 |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| WO2008145616A1 (fr) | 2007-05-25 | 2008-12-04 | Abbott Gmbh & Co. Kg | Composés hétérocycliques comme modulateurs positifs du récepteur métabotropique du glutamate 2 (récepteur mglu2) |
| WO2009004430A1 (fr) | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones et composés hétérocycliques apparentés comme potentialisateurs de récepteurs du glutamate |
| EP2194045A4 (fr) | 2007-08-30 | 2011-09-21 | Takeda Pharmaceutical | Dérivé de pyrazole substitué |
| EP2215073A4 (fr) | 2007-10-31 | 2011-04-06 | Merck Sharp & Dohme | Modulation du sommeil avec des antagonistes du récepteur nr2b |
| KR20100135847A (ko) | 2008-03-27 | 2010-12-27 | 에보텍 뉴로사이언시즈 게엠베하 | Nmda nr2b―서브타입 선택적 길항제를 사용한 질병 치료 방법 |
| US20110130384A1 (en) | 2008-06-25 | 2011-06-02 | Takeda Pharmaceutical Company Limited | Amide compound |
| CN102171210B (zh) | 2008-08-05 | 2014-04-23 | 第一三共株式会社 | 咪唑并吡啶-2-酮衍生物 |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| ES2466341T3 (es) | 2008-10-16 | 2014-06-10 | Janssen Pharmaceuticals, Inc. | Derivados de indol y benzomorfolina como moduladores de receptores de glutamato metabotrópicos |
| EP2379561B1 (fr) | 2008-11-25 | 2015-11-04 | University Of Rochester | Inhibiteurs de mlk et procédés d'utilisation |
| EP2408753A4 (fr) | 2009-03-20 | 2012-11-07 | Univ Brandeis | Composés et procédés pour traiter les infections microbiennes gastro-intestinales mammaliennes |
| WO2011022348A1 (fr) | 2009-08-18 | 2011-02-24 | Janssen Pharmaceutica Nv | Modulateurs d'éthylène diamine d'une amide hydrolase d'acide gras |
| EP2579717A4 (fr) | 2010-06-09 | 2013-12-11 | Merck Sharp & Dohme | Modulateurs allostériques positifs de mglur2 |
| WO2011158108A2 (fr) * | 2010-06-16 | 2011-12-22 | Purdue Pharma L.P. | Indoles à substitution aryle et leur utilisation |
| EP2669270B1 (fr) * | 2011-01-28 | 2018-01-03 | Sato Pharmaceutical Co., Ltd. | Composés apparentés à l'indole en tant qu'inhibiteurs d'urat1 |
| JP2012188363A (ja) | 2011-03-09 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | アザベンゾイミダゾロン誘導体 |
| ES2552836T3 (es) | 2011-09-19 | 2015-12-02 | Sanofi | N-[4-(1H-pirazolo[3,4-b]pirazin-6-il)-fenil]-sulfonamidas y su uso como productos famacéuticos |
| WO2013060029A1 (fr) | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp | Modulateurs allostériques des récepteurs métabotropiques du glutamate |
| US9434743B2 (en) | 2012-03-02 | 2016-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
| JOP20130273B1 (ar) | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
| WO2014124651A1 (fr) | 2013-02-15 | 2014-08-21 | Københavns Universitet | Dérivés de pyrrolidine-2-acide carboxylique utilisés en tant qu'antagonistes de iglur |
| EP2970200A1 (fr) | 2013-03-13 | 2016-01-20 | Abbvie Inc. | Inhibiteurs de pyridine cdk9 kinase |
| RU2680100C9 (ru) | 2013-03-15 | 2019-04-18 | Плексксикон Инк. | Гетероциклические соединения и их применения |
| SI3010503T1 (sl) | 2013-06-21 | 2020-07-31 | Zenith Epigenetics Ltd. | Novi biciklični inhibitorji bromodomene |
| RU2712220C2 (ru) * | 2013-07-31 | 2020-01-27 | Мерк Патент Гмбх | Пиридины, пиримидины и пиразины в качестве ингибиторов тирозинкиназы брутона и их применение |
| ES2791186T3 (es) | 2014-08-15 | 2020-11-03 | Janssen Pharmaceuticals Inc | Triazoles como inhibidores de receptores NR2B |
| HUE049278T2 (hu) | 2014-08-15 | 2020-09-28 | Janssen Pharmaceuticals Inc | Pirazolok |
| WO2016081649A1 (fr) | 2014-11-18 | 2016-05-26 | Emory University | Dérivés de thiéno[2,3-d]pyrimidin-4-one utilisés comme modulateurs de nmdar et leurs utilisations associées |
| MA41803A (fr) * | 2015-03-24 | 2018-01-30 | Almirall Sa | Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques |
| AU2016291158B2 (en) | 2015-07-09 | 2020-04-30 | Janssen Pharmaceutica Nv | Substituted 4-azaindoles and their use as GluN2B receptor modulators |
| JP6923543B2 (ja) | 2016-02-10 | 2021-08-18 | ヤンセン ファーマシューティカ エヌ.ベー. | Nr2b選択的nmda調節因子としての置換1,2,3−トリアゾール |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
| IL271149B2 (en) | 2017-06-14 | 2024-05-01 | Trevena Inc | Compounds for modulating s1p1 activity and methods of using the same |
| US10766893B2 (en) | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| US11008302B2 (en) | 2018-04-04 | 2021-05-18 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators |
| CN110294756A (zh) * | 2019-06-04 | 2019-10-01 | 广州市原子高科同位素医药有限公司 | GluN2B亚基靶向型中枢神经系统正电子示踪剂及其制备 |
| US11459336B2 (en) | 2019-06-14 | 2022-10-04 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as GluN2B receptor modulators |
| CR20210580A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b |
| BR112021025136A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Pirazolo[4,3-b]piridinas substituídas e seu uso como moduladoras do receptor de glun2b |
| WO2020249802A1 (fr) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Pyrazolo-pyrazines substituées et leur utilisation en tant que modulateurs du récepteur de glun2b |
| MX2021015508A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Carbamatos de piridina y su uso como moduladores del receptor glun2b. |
| WO2020249785A1 (fr) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Pyrazolo-pyridines hétéroaromatiques substituées et leur utilisation en tant que modulateurs du récepteur glun2b |
-
2020
- 2020-06-12 CR CR20210580A patent/CR20210580A/es unknown
- 2020-06-12 MX MX2021015506A patent/MX2021015506A/es unknown
- 2020-06-12 EP EP20737362.2A patent/EP3983075A1/fr active Pending
- 2020-06-12 MA MA056196A patent/MA56196A/fr unknown
- 2020-06-12 JO JOP/2021/0328A patent/JOP20210328A1/ar unknown
- 2020-06-12 AU AU2020290016A patent/AU2020290016A1/en active Pending
- 2020-06-12 CA CA3142996A patent/CA3142996A1/fr active Pending
- 2020-06-12 WO PCT/EP2020/066392 patent/WO2020249792A1/fr not_active Ceased
- 2020-06-12 KR KR1020227001089A patent/KR20220024511A/ko not_active Withdrawn
- 2020-06-12 CN CN202080043675.8A patent/CN113993868A/zh active Pending
- 2020-06-12 SG SG11202112407PA patent/SG11202112407PA/en unknown
- 2020-06-12 TW TW109119835A patent/TW202112774A/zh unknown
- 2020-06-12 BR BR112021024856A patent/BR112021024856A2/pt unknown
- 2020-06-12 PE PE2021001941A patent/PE20220386A1/es unknown
- 2020-06-12 US US16/899,823 patent/US11618750B2/en active Active
-
2021
- 2021-11-26 CO CONC2021/0016003A patent/CO2021016003A2/es unknown
- 2021-12-02 DO DO2021000251A patent/DOP2021000251A/es unknown
- 2021-12-09 IL IL288859A patent/IL288859A/en unknown
- 2021-12-09 CL CL2021003277A patent/CL2021003277A1/es unknown
- 2021-12-14 EC ECSENADI202190478A patent/ECSP21090478A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3983075A1 (fr) | 2022-04-20 |
| CO2021016003A2 (es) | 2021-12-10 |
| TW202112774A (zh) | 2021-04-01 |
| KR20220024511A (ko) | 2022-03-03 |
| MX2021015506A (es) | 2022-02-10 |
| JOP20210328A1 (ar) | 2023-01-30 |
| CL2021003277A1 (es) | 2022-08-19 |
| AU2020290016A1 (en) | 2022-01-06 |
| DOP2021000251A (es) | 2022-04-18 |
| ECSP21090478A (es) | 2022-01-31 |
| IL288859A (en) | 2022-02-01 |
| CA3142996A1 (fr) | 2020-12-17 |
| US20210017168A1 (en) | 2021-01-21 |
| WO2020249792A1 (fr) | 2020-12-17 |
| BR112021024856A2 (pt) | 2022-01-18 |
| PE20220386A1 (es) | 2022-03-18 |
| CN113993868A (zh) | 2022-01-28 |
| CR20210580A (es) | 2022-01-31 |
| US11618750B2 (en) | 2023-04-04 |
| SG11202112407PA (en) | 2021-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA56196A (fr) | Pyrazolo-pyridine amides substitués et leur utilisation en tant que modulateurs du récepteur glun2b | |
| MA56183A (fr) | Pyrazolo-pyridines hétéroaromatiques substituées et leur utilisation en tant que modulateurs du récepteur glun2b | |
| MA52244A (fr) | Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b | |
| EP3867216A4 (fr) | Modulateurs du récepteur des androgènes et leurs méthodes d'utilisation | |
| EP3893871C0 (fr) | Dérivés de benzimidazolone, et analogues de ceux-ci, en tant que modulateurs d'il-17 | |
| IL287379A (en) | Modulators of the integrated stress response pathway | |
| DK3743418T3 (da) | Chemokinreceptormodulatorer og anvendelser deraf | |
| DK3743406T3 (da) | Tmem16a modulatorer | |
| MA44075A (fr) | Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1 | |
| MA52284A (fr) | Anticorps anti-hla-g et leur utilisation | |
| EP3746447C0 (fr) | Modulateurs spiro-lactames des récepteurs nmda et leurs utilation | |
| EP3899024A4 (fr) | Modulateurs de l'expression de hsd17b13 | |
| IL281492A (en) | Modulators of pnpla3 expression | |
| HUE062866T2 (hu) | TREX-1 modulátorok | |
| EP3490994C0 (fr) | Modulateurs spiro-lactames et bis-spiro-lactames des récepteurs nmda et leurs utilisations | |
| IL285067A (en) | Mtorc modulators and uses thereof | |
| EP3516655A4 (fr) | Appareil de réglage de tension de décalage dans un tampon d'entrée | |
| EP3565543A4 (fr) | Modulateurs du récepteur opioïde de type mu | |
| EP3600290C0 (fr) | Nouveaux modulateurs du récepteur sigma 2 et leur procédé d'utilisation | |
| EP3758704A4 (fr) | Modulateurs de l'expression d'irf4 | |
| EP3558318A4 (fr) | Modulateurs des récepteurs nmda et utilisations de ceux-ci | |
| EP3717462A4 (fr) | Composés de sulfonamide et leur utilisation | |
| EP3764154C0 (fr) | Appareil d'affichage | |
| MA52555A (fr) | Modulateurs du récepteur des oestrogènes | |
| EP3931328A4 (fr) | Modulateurs de l'expression de malat1 |